Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the United ...

Speaker(s)

Jagannath S1, Joseph N2, Chinaeke E3, Crivera C4, Fu A3, Garrett A5, Shah N6
1Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2Janssen Scientific Affairs, LLC, Phoenixville, PA, USA, 3Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA, 5Legend Biotech Inc., Piscataway, NJ, USA, 6University of California San Francisco, San Francisco, CA, USA

Presentation Documents

OBJECTIVES: Proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have significantly improved survival in Multiple Myeloma (MM) patients, but patients continue to progress or become refractory to these treatments, requiring the use of additional lines of therapy (LOTs). This retrospective study assessed real world healthcare resource utilization (HCRU) and subsequent costs in MM patients in the United States, after receiving 1-3 LOTs, exposed to a PI and an IMiD, and exposed to (and discontinued) lenalidomide.

METHODS: Eligible MM patients (≥18 years) were selected from IBM MarketScan Commercial and Medicare supplemental databases (January 2012-April 2021). The study population included patients who received ≥1 subsequent LOT after January 1, 2017 (to reflect contemporary healthcare costs). A subgroup of patients with at least 12 months of follow-up after initiating the subsequent LOT was assessed as a sensitivity analysis.

RESULTS: The study population included 607 MM patients; the mean age was 60.0 years and 59.0% were male. During a median follow-up of 11.5 months, for all-cause healthcare use, there were an average of 1.60 in-patient hospitalizations, 12.7 days of in-patient hospital stay, and 55.4 outpatient visits. Mean total all-cause healthcare costs per patient was $405,999 (equivalent to $37,516 per patient per month [PPPM]). MM-related costs per patient accounted for 93.1% ($378,115) of total all-cause healthcare costs. In the subgroup of patients with at least 12 months of follow-up (N=293, median follow-up of 21.6 months), the mean total all-cause healthcare costs per patient was $623,002 (equivalent to $30,716 PPPM).

CONCLUSIONS: In this database study using US administrative claims, MM patients with exposure to PI and IMiD drug classes and receiving subsequent MM treatments continue to incur high healthcare costs, with the majority of these costs being MM-related.

Code

EE437

Topic

Economic Evaluation, Study Approaches

Disease

No Additional Disease & Conditions/Specialized Treatment Areas